Abstract
Colorectal cancer (CRC) is the fourth most common cancer in the world. If detected at an early stage, treatment often might lead to cure. Of course prevention is better than cure. Epidemiological studies reveal that having a healthy diet often protects from CRC development. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are a number of agents making their way into clinical trials by estimating their effects on biomarkers expression. Also, some are awaiting the preclinical efficacy and safety results to enter into clinical trials. Oncologic researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective. However, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target agents needs to be evaluated in appropriate animal models for their efficacies as well as toxicities. This review focuses on the few of the potential molecular targets and their biomarkers in CRC development.
Current Enzyme Inhibition
Title: Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Volume: 5 Issue: 1
Author(s): Yumiko Yasui, Mihe Kim, Takeru Oyama and Takuji Tanaka
Affiliation:
Abstract: Colorectal cancer (CRC) is the fourth most common cancer in the world. If detected at an early stage, treatment often might lead to cure. Of course prevention is better than cure. Epidemiological studies reveal that having a healthy diet often protects from CRC development. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are a number of agents making their way into clinical trials by estimating their effects on biomarkers expression. Also, some are awaiting the preclinical efficacy and safety results to enter into clinical trials. Oncologic researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective. However, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target agents needs to be evaluated in appropriate animal models for their efficacies as well as toxicities. This review focuses on the few of the potential molecular targets and their biomarkers in CRC development.
Export Options
About this article
Cite this article as:
Yasui Yumiko, Kim Mihe, Oyama Takeru and Tanaka Takuji, Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets, Current Enzyme Inhibition 2009; 5 (1) . https://dx.doi.org/10.2174/157340809787314247
DOI https://dx.doi.org/10.2174/157340809787314247 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Interaction of Tumor Suppressor p53 with DNA and Proteins
Current Pharmaceutical Biotechnology MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine The Redox Biology of Schistosome Parasites and Applications for Drug Development
Current Pharmaceutical Design Epigenetics of Aging
Current Genomics LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies
Letters in Drug Design & Discovery CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Editorial (Thematic Issue: Harmful and Beneficial Effect of Aspirin on Gastrointestinal Tract)
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry The Anticancer Role of Omega-3 Polyunsaturated Fatty Acids was Closely Associated with the Increase in Genomic DNA Hydroxymethylation
Anti-Cancer Agents in Medicinal Chemistry Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design